InsidersTradesSigma
Total declarations
Company
▲ Purchases (7 ops.)
▼ Sales (0 ops.)
Browse the detailed record of transactions filed by Byam Rebecca, Chief Financial Officer. Director active across 1 companies, notably HCW Biologics Inc.. Cumulatively, 9 disclosures have been logged. Total volume traded: €506k. The latest transaction was disclosed on 13 June 2022 — Acquisition. Regulator: SEC (Form 4). The full history is openly available.
Declarations9 total
€15,1827,596 shares@ €1.99870.18% mcap3.0% of flow
Common Stock
SEC:0001209191-22-037110:0·
Ideal exit: 10 Mar 2023 (T+270)
€3,36227,000 shares@ €0.12450.041% mcap1.4% of flow
Common Stock
SEC:0001209191-21-066900·
€3,36227,000 shares@ €0.12450.041% mcap0.7% of flow
Common Stock
SEC:0001209191-21-066900:0·
€37,66410,000 shares@ €3.76640.46% mcap15.2% of flow
Common Stock
SEC:0001209191-21-055532·
Ideal exit: 16 May 2022 (T+270)
€37,66410,000 shares@ €3.76640.46% mcap7.4% of flow
Common Stock
SEC:0001209191-21-055532:0·
Ideal exit: 16 May 2022 (T+270)
€37,66410,000 shares@ €3.76640.46% mcap15.2% of flow
Common Stock
SEC:0001209191-21-053049·
Ideal exit: 16 May 2022 (T+270)
€37,66410,000 shares@ €3.76640.46% mcap7.4% of flow
Common Stock
SEC:0001209191-21-053049:0·
Ideal exit: 16 May 2022 (T+270)
€169,88425,000 shares@ €6.79542.07% mcap68.3% of flow
Common Stock
SEC:0001209191-21-048079·
Ideal exit: 18 Apr 2022 (T+270)
€169,88425,000 shares@ €6.79542.07% mcap33.2% of flow
Common Stock
SEC:0001209191-21-048079:0·
Ideal exit: 18 Apr 2022 (T+270)
9 of 9 declarations
About Byam Rebecca
Rebecca Byam is the Chief Financial Officer at HCW Biologics Inc. She is responsible for the company's financial management, including financial planning and performance analysis. Her expertise is essential to support the company's growth and profitability.
